| Name | 6RK73 | 
|---|
| Description | 6RK73 is a covalent irreversible and specific UCHL1 inhibitor with an IC50 of 0.23 µM. 6RK73 shows almost no inhibition of UCHL3 (IC50=236 µM). 6RK73 specifically inhibit UCHL1 activity in breast cancer[1]. | 
|---|---|
| Related Catalog | |
| Target | IC50: 0.23 µM (UCHL1), 236 µM (UCHL3)[1] | 
| In Vitro | 6RK73 (5 µM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells[1]. 6RK73(5 µM; 24-48 hours) results migration significantly slower than the DMSO control group in MDA-MB-436 cells[1]. Cell Viability Assay[1] Cell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 24, 48 hours Result: Migrated significantly slower than the DMSO control group Western Blot Analysis[1] Cell Line: MDA-MB-436 cells Concentration: 5 µM Incubation Time: 1, 2, 3 hours Result: Displayed strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels. | 
| In Vivo | 6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish[1]. | 
| References | 
| Molecular Formula | C13H17N5O2S | 
|---|---|
| Molecular Weight | 307.37 | 
| Hazard Codes | Xi | 
|---|